Click on the links below to view completed BrIDGs projects:
- Advanced Studies with 5HMF — Most Potent Anti-Sickling Agent
- A Pharmacological and Toxicological Evaluation of the Gene Transfer Vectors sc-rAAV2.5IL-1Ra (Rat) and scr-AAV2.5IL-1Ra (Human) in Rats
- Alternative Formulations of Decitabine to Reactivate Fetal Hemoglobin Production
- Biomimetic Actinide Decorporation Agents: Enabling Availability
- cGMP Synthesis of the Selective Kappa Opioid Receptor Antagonist JDTic
- Developing SRX246 for Stress-Related Affective Illness
- Development of an ApoA-1 Mimetic Peptide for Treatment of Atherosclerosis
- Development of Assays to Detect Anti-Drug Antibodies Against ACP-501
- Development of Bone Morphogenetic Protein Inhibitors to Treat Blood and Bone Disorders
- Development of Exendin-(9-39) for the Treatment of Congenital Hyperinsulinism
- Development of HGF Mimetic (Refanalin) for Hepatic Fibrosis
- Development of Minihepcidins for the Treatment of Beta Thalassemia
- Development of Neurosteroids for Lysosomal Storage Disorders
- Development of P-321 for Chronic Dry Eye
- Development of Propofol Hemisuccinate for the Treatment of Epilepsy
- HBN-1 Regulated Hypothermia Formulation and Evaluation of Toxicity
- IND-Enabling Studies on AAV2-GDNF for Parkinson’s Disease
- IND-Enabling Toxicology and Safety Pharmacology Studies for a First-in-Class CPG-Activating Drug Treatment (SPINALON) Against Chronic Spinal Cord Injury
- IND-Enabling Toxicology and Safety Pharmacology Studies of ATN-161 for the Treatment of Crohn’s Disease
- Inhibitors of Glutaminase 2 as Therapeutic Agents for Neuro-Oncological Diseases and Celiac Sprue
- Large-Scale Synthesis of Clozapine-N-Oxide
- Long-Acting Parathyroid Hormone Analog for Treatment of Hypoparathyroidism
- Manufacture of AAV2-AADC for the Treatment of AADC Deficiency
- Manufacture of RLIP76-LyoPL for Acute Radiation Syndrome
- Metarrestin for the Treatment of Pancreatic Cancer
- Metastin Administration in Humans: Support for Preclinical Toxicology Studies
- A Novel Drug Candidate for the Treatment of Diabetic Retinopathy
- Novel PDE Inhibitors for Treatment of Cognitive Dysfunction in Schizophrenia
- Novel Pre-Hospital Therapy of Myocardial Infarction
- A Potent Oral Therapy for Cytomegalovirus Infection
- Preclinical Development of CDD-0102 for the Treatment of Alzheimer’s Disease
- Preclinical Development of EDN-OL1 for Alzheimer’s Disease
- Redox Encrypted Therapeutics for Treatment of Friedreich’s Ataxia
- Safety Pharmacology Studies for Beta Thalassemia
- Single-Chain Urokinase Plasminogen-Activating Factor
- Small Molecule Treatment for Rheumatoid Arthritis
- Using the Preimplantation Factor (PIF) to Treat Graft-Versus-Host Disease